MA46541A - Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a - Google Patents

Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a

Info

Publication number: MA46541A
Authority: MA; Morocco
Prior art keywords: nephropathy; immunoglobulin; methods; human subject; reducing proteinuria
Prior art date: 2016-10-13

Application number

MA046541A

Other languages

English (en)

Inventor

Nigel John Brunskill

Gregory A Demopulos

Tom Dudler

Hans-Wilhelm Schwaeble

Original Assignee

Omeros Corp

Univ Leicester

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-13

Filing date

2017-10-12

Publication date

2019-08-21

2017-01-05 Priority claimed from US15/399,524 external-priority patent/US10736960B2/en

2017-03-27 Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en

2017-10-12 Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp

2019-08-21 Publication of MA46541A publication Critical patent/MA46541A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Environmental Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

MA046541A 2016-10-13 2017-10-12 Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a MA46541A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201662407979P	2016-10-13	2016-10-13
US15/399,524 US10736960B2 (en)	2016-01-05	2017-01-05	Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en)	2016-01-05	2017-03-27	Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P	2017-06-30	2017-06-30

Publications (1)

Publication Number	Publication Date
MA46541A true MA46541A (fr)	2019-08-21

Family

ID=61906454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA046541A MA46541A (fr)	2016-10-13	2017-10-12	Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a

Country Status (19)

Country	Link
EP (1)	EP3525798A4 (fr)
JP (1)	JP6893554B2 (fr)
KR (1)	KR102348939B1 (fr)
CN (2)	CN116726163A (fr)
AU (1)	AU2017342428B2 (fr)
BR (1)	BR112019007426A2 (fr)
CA (2)	CA3039927C (fr)
CL (2)	CL2019000909A1 (fr)
GE (2)	GEP20247587B (fr)
IL (1)	IL265981B2 (fr)
JO (1)	JOP20190068B1 (fr)
MA (1)	MA46541A (fr)
MX (1)	MX2019004074A (fr)
MY (1)	MY205849A (fr)
PH (1)	PH12019500711B1 (fr)
SG (1)	SG11201902941UA (fr)
UA (1)	UA126908C2 (fr)
WO (1)	WO2018071701A1 (fr)
ZA (1)	ZA201902933B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111419860A (zh) *	2020-03-19	2020-07-17	长春市儿童医院	一种肾小球分叶状肾病造模方法
CN115215937B (zh)	2021-04-15	2023-05-26	上海麦济生物技术有限公司	抗人masp-2抗体及其制备方法和应用
CA3240483A1 (fr)	2021-12-10	2023-06-15	Thomas Dudler	Anticorps therapeutiques qui se lient au domaine serine protease de masp-2 et leurs utilisations
CN116392488B (zh) *	2023-05-22	2025-03-28	中南大学湘雅医院	一种生物碱化合物在制备防治糖尿病肾病的药物中的应用
CN117016486B (zh) *	2023-07-20	2024-05-14	上海澎立生技医药研究有限公司	一种IgA肾病合并膜性肾病的动物模型构建方法
WO2026026712A1 (fr) *	2024-07-31	2026-02-05	前沿生物药业(南京)股份有限公司	Arnsi pour inhiber l'expression du gene masp2 et son modificateur et son utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE034760T2 (en) *	2003-05-12	2018-02-28	Helion Biotech Aps	Masp-2-T binding antibodies
US20140056873A1 (en) *	2004-06-10	2014-02-27	University Of Leicester	Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US8840893B2 (en) *	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) *	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en)	2006-03-31	2009-12-01	Eastman Kodak Company	Method of making a multilevel halftone screen
EP3150635A3 (fr) *	2009-10-16	2017-06-21	Omeros Corporation	Procédés de traitement de la coagulation intravasculaire disséminée par inhibition de l'activation du complément masp-2 dépendant
WO2012100262A1 (fr) *	2011-01-21	2012-07-26	Fibrogen, Inc.	Méthode thérapeutique utilisant un anticorps anti-ctgf
DK2694108T3 (en) *	2011-04-08	2018-08-20	Univ Leicester	METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) *	2011-04-08	2017-05-09	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
HUE049154T2 (hu) *	2011-05-04	2020-09-28	Omeros Corp	Készítmények a MASP-2-függõ komplement-aktiválás gátlására
CA2906096C (fr) *	2013-03-15	2022-03-15	Omeros Corporation	Methodes de generation d'anticorps porteurs de peptide bioactif et compositions les comprenant
RS61351B1 (sr) *	2013-10-17	2021-02-26	Omeros Corp	Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
CA3010593C (fr) *	2016-01-05	2024-02-13	University Of Leicester	Methodes d'inhibition d'une fibrose chez un sujet ayant besoin d'un tel traitement
JOP20170170B1 (ar) *	2016-08-31	2022-09-15	Omeros Corp	صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

2017
- 2017-10-12 AU AU2017342428A patent/AU2017342428B2/en active Active
- 2017-10-12 UA UAA201904866A patent/UA126908C2/uk unknown
- 2017-10-12 CA CA3039927A patent/CA3039927C/fr active Active
- 2017-10-12 MY MYPI2019001798A patent/MY205849A/en unknown
- 2017-10-12 IL IL265981A patent/IL265981B2/en unknown
- 2017-10-12 MX MX2019004074A patent/MX2019004074A/es unknown
- 2017-10-12 KR KR1020197012865A patent/KR102348939B1/ko active Active
- 2017-10-12 GE GEAP201715070A patent/GEP20247587B/en unknown
- 2017-10-12 SG SG11201902941UA patent/SG11201902941UA/en unknown
- 2017-10-12 JO JOJO/P/2019/0068A patent/JOP20190068B1/ar active
- 2017-10-12 JP JP2019520140A patent/JP6893554B2/ja active Active
- 2017-10-12 CN CN202310450575.2A patent/CN116726163A/zh active Pending
- 2017-10-12 PH PH1/2019/500711A patent/PH12019500711B1/en unknown
- 2017-10-12 EP EP17861108.3A patent/EP3525798A4/fr active Pending
- 2017-10-12 BR BR112019007426-0A patent/BR112019007426A2/pt not_active Application Discontinuation
- 2017-10-12 WO PCT/US2017/056386 patent/WO2018071701A1/fr not_active Ceased
- 2017-10-12 GE GEAP202516204A patent/GEP20267856B/en unknown
- 2017-10-12 MA MA046541A patent/MA46541A/fr unknown
- 2017-10-12 CA CA3210384A patent/CA3210384A1/fr active Pending
- 2017-10-12 CN CN201780060710.5A patent/CN110177557A/zh active Pending
2019
- 2019-04-04 CL CL2019000909A patent/CL2019000909A1/es unknown
- 2019-05-10 ZA ZA2019/02933A patent/ZA201902933B/en unknown
- 2019-11-28 CL CL2019003485A patent/CL2019003485A1/es unknown

Also Published As

Publication number	Publication date
NZ753260A (en)	2021-11-26
AU2017342428A1 (en)	2019-05-23
JP6893554B2 (ja)	2021-06-23
GEP20247587B (en)	2024-01-25
EP3525798A4 (fr)	2020-07-08
WO2018071701A1 (fr)	2018-04-19
CN116726163A (zh)	2023-09-12
AU2017342428B2 (en)	2021-02-04
IL265981A (en)	2019-06-30
GEP20267856B (en)	2026-02-10
SG11201902941UA (en)	2019-05-30
EP3525798A1 (fr)	2019-08-21
PH12019500711A1 (en)	2019-11-18
MX2019004074A (es)	2019-06-10
JOP20190068B1 (ar)	2024-12-22
CN110177557A (zh)	2019-08-27
KR102348939B1 (ko)	2022-01-12
PH12019500711B1 (en)	2024-04-17
KR20190063475A (ko)	2019-06-07
MY205849A (en)	2024-11-15
CL2019000909A1 (es)	2019-06-14
CL2019003485A1 (es)	2020-04-13
CA3039927A1 (fr)	2018-04-19
JOP20190068A1 (ar)	2019-04-01
CA3210384A1 (fr)	2018-04-19
UA126908C2 (uk)	2023-02-22
JP2019534271A (ja)	2019-11-28
CA3039927C (fr)	2023-10-10
IL265981B1 (en)	2025-01-01
IL265981B2 (en)	2025-05-01
BR112019007426A2 (pt)	2019-07-02
ZA201902933B (en)	2023-05-31

Publication	Publication Date	Title
IL262092A (en)	2018-11-29	Humanized anti-pacap antibodies and uses thereof
IL258332A (en)	2018-05-31	Antibody factors specific for human differentiation group 19 and their uses
IL261442A (en)	2018-10-31	Tgfb1-binding immunoglobulins and use thereof
EP3430731A4 (fr)	2019-10-09	Architecture d'iugw
DK3347030T3 (da)	2021-08-09	Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
EP3349581A4 (fr)	2019-04-24	Modulateurs des protéines du noyau de l'hépatite b
EP3494137C0 (fr)	2025-07-02	Anticorps contre ctla-4 humain
HUE053239T2 (hu)	2021-06-28	Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
MA42924A (fr)	2018-08-01	Variants optimisés d'anticorps anti-vegf
IL262776A (en)	2018-12-31	Humanized anti-il-1r3 antibodies
EP3325963A4 (fr)	2019-08-14	Amélioration de l'estimation de globules
MA45684A (fr)	2019-05-22	Protéine d'apport du cerveau
LT3532499T (lt)	2021-08-10	Antikūnai prieš il-33 ir jų panaudojimas
IL258259A (en)	2018-05-31	Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
HRP20251683T1 (hr)	2026-02-13	Humanizirana anti-acth antitijela i njihova uporaba
IL270244A (en)	2019-12-31	Antibody against human semaphorin 4D
DK2994160T3 (da)	2019-08-12	Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g
EP3327036A4 (fr)	2019-03-13	Anticorps anti-egfr spécifique d'une tumeur et application associée
EP3530828A4 (fr)	2020-06-03	Raccord d'articulation
IL262588A (en)	2018-12-31	Humanized anti-basigin antibodies and the use thereof
EP3571751A4 (fr)	2020-01-08	Architecture d'optimiseurs central/ distribués
IL258924A (en)	2018-06-28	Humanized anti-dkk2 antibody and uses thereof
EP3405821A4 (fr)	2019-08-14	Inverseur d'image fovéale
IL249142B (en)	2022-02-01	Controlling the formation of disulfide bonds in protein solutions by adding reducing agents
IL288090A (en)	2022-01-01	Expression of antigen-binding proteins in the nervous system